title: Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries.
abstract: BACKGROUND
  Calcitonin gene-related peptide (CGRP) is a neuronal messenger in intracranial sensory nerves and is considered to play a significant role in migraine pathophysiology.
  
  
  METHODS
  We investigated the effect of the CGRP receptor antagonist, telcagepant, on CGRP-induced cranial vasodilatation in human isolated cerebral and middle meningeal arteries. We also studied the expression of the CGRP receptor components in cranial arteries with immunocytochemistry. Concentration response curves to αCGRP were performed in human isolated cerebral and middle meningeal arteries in the absence or presence of telcagepant. Arterial slices were stained for RAMP1, CLR and actin in a double immunofluorescence staining.
  
  
  RESULTS
  In both arteries, we found that: (i) telcagepant was devoid of any contractile or relaxant effects per se; (ii) pretreatment with telcagepant antagonised the αCGRP-induced relaxation in a competitive manner; and (iii) immunohistochemistry revealed expression and co-localisation of CLR and RAMP1 in the smooth muscle cells in the media layer of both arteries.
  
  
  CONCLUSIONS
  Our findings provide morphological and functional data on the presence of CGRP receptors in cerebral and meningeal arteries, which illustrates a possible site of action of telcagepant in the treatment of migraine.
authors.affiliation: Department of Internal Medicine, Lund University Hospital, Lund, Sweden. lars.edvinsson@med.lu.se
authors.forename: Lars
authors.initials: L
authors.lastname: Edvinsson
authors.forename: Kayi Y
authors.initials: KY
authors.lastname: Chan
authors.forename: Sajedeh
authors.initials: S
authors.lastname: Eftekhari
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Nilsson
authors.forename: René
authors.initials: R
authors.lastname: de Vries
authors.forename: Hans
authors.initials: H
authors.lastname: Säveland
authors.forename: Clemens M F
authors.initials: CM
authors.lastname: Dirven
authors.forename: A H Jan
authors.initials: AH
authors.lastname: Danser
authors.forename: Antoinette
authors.initials: A
authors.lastname: MaassenVanDenBrink
mesh_terms: D000368:Aged; D001381:Azepines / Q000494:pharmacology*; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D058286:Calcitonin Receptor-Like Protein; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D008576:Meningeal Arteries / Q000187:drug effects*; D008875:Middle Aged; D058262:Receptor Activity-Modifying Protein 1 / Q000187:drug effects / Q000378:metabolism; D018003:Receptors, Calcitonin / Q000187:drug effects / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects
chemical_list: D001381:Azepines; C545578:CALCRL protein, human; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D058286:Calcitonin Receptor-Like Protein; D007093:Imidazoles; C545502:RAMP1 protein, human; D058262:Receptor Activity-Modifying Protein 1; D018003:Receptors, Calcitonin; C525458:telcagepant